geny2

28.

Warner E, et a!.: Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashke-nazi Jewish women with breast cancer. J Natl Cancerlnst 1999; 91:1241-1247.

Jakubowska A, et al.: BRCA2 gene mutation in families with aggregations ofbreastand stornach cancers.

BrJ Cancer 2002; 87: 888-891.

Jakubowska A, et al.: A high freąuency of BRCA2 gene mutations in Poiish families with ovarian and słomach cancer. Eur J Hum Genet 2003; 11: 955-958.    ,*a

Kwiatkowska E, et al.: BRCA2 germline mutations in małe breast cancer patients in the Poiish popula- ' §j! tion. Hum Mutat 2001; 17: 73.

Boyd J, et al.: Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000; 283; 2260-2265.

Malkin D, et al.: Germline p53 mutations in a familiar syndrome of breast cancer, sarcomas and other neoplasms. Science 1990; 250: 1233-1238.

Nelen MR, et al.: Loćalization of the gene forCowden disease to chromosome 10q22-23. Nat Genet 1996; 13:114-116.    '!■

Hanssen AM, Fryns JP: Cowden syndrome. J Med Genet 1995; 32: 117-119.

Risinger Jl, et al.: Molecular genetic evidence of the occurrence of breast cancer as on integral tumor in patients with the hereditary nonpolyposis colorectal carcinoma syndrome. Cancer 1996; 77: 1836-1843. Spigelman AD, Murday V, Phillips RK: Cancer and Peutz-Jeghers syndrome. Gut 1989; 30: 1588-1590.    :'i

Cohen MM Jr: A comprehensive and critical assessment of overgrowth and overgrowth syndromes. Adv Hum Genet 1989; 18: 181-303, 373-376.

Shiloh Y: Ataxia telangiectasia: closer to unraveling the mystery. Eur J Hum Genet 1995; 3: 116-138.

Lynch HT, Kapłan AR, Lynch JF: Klinefelter syndrome and cancer. A family study. JAMA 1974; 229: 809-811.

Wooster R, et al.: A germline mutation in the androgen receptor in two brothers with breast cancer and Reifenstein syndrome. Nat Genet 1992; 2: 132-134.

Lindblom A, et al.: Predisposition for breast cancer in carriers of constilutional translocation 1 lq;22q. Am J Hum Genet 1994; 54: 871 -876.

Naród SA, et al.: Orał contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinicai Study Group. N Engl J Med 1998; 339: 424-428.

McLaughlin JR, et al.: Hereditary Ovarian Cancer Clinicai Study Group. Reproductive risk factors for oyarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 2007; 8: 26-34.    ?

Naród SA, et a.: Orał contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carri-ers. J Nat! Cancer Inst 2002; 94: 1773-1779.

Grabrick DM, et al.; Risk of breast cancer with orał contraceplive use in women with a family history of breast cancer. JAMA 2000; 284: 1791-1798.

Armstrong K, et al.: Hormon replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCAII2 mutations: a decision analysis. J Clin Oncol 2004; 22: 1045-1054.

Rebbeck TR, et al.: Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduc-tion After Bilateral Prophylactic Oophorectomy in BRCAI and BRCA2 Mutation Carriers: The PROSE Study Group. J Clin Oncol 2005; 23: 7804-7810.

Buchet-Poyau K, et al.: Search for the second Peutz-Jeghers syndrome locus: exclusion of the STK13, PRKCG, KLK10, and PSCD2 genes on chromosome 19 and the STK1 IIP gene on chromosome 2. Cyto-genet Genome Res 2002; 97: 171-178.

Gronwald J, et al.: Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCAI mutation carriers from Poland. Breast Cancer Res Treat 2006; 95: 105-109.

Naród SA: Hormonal prevention of hereditary breast cancer. Ann N Y Acad Sci 2001; 952: 36-43. Kotsopoulos J, et al.: Age at First birth and the risk of breast cancer in BRCAI and BRCA2 mutation carri-ers. Breast Cancer Res Treat 2007; 105:221-228.

Gronwald J, et al.: Hereditary Breast Cancer Clinicai Study Group. Tamoxifen and contralateral breast cancer in BRCAI and BRCA2 carriers: an update. Int J Cancer 2006; 118: 2281-2284.

Naród SA, et al.: Hereditary Breast Cancer Clinicai Study Group. Tamoxifen and risk of contralateral breast cancer in BRCAI and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinicai Study Group. Lancet 2000; 356: 1876-1881.

Kowalska E, et al.: Increased rates of chromosome breakage in BRCAI carriers are normalized by orał se-lenium supplementation. Cancer Epidemio! Biomarkers Prev 2005; 14: 1302-1306.

Mehkisz3k J, et al.: Attitudes toward preventive oophorectomy among BRCAI mutation carriers in Poland. Eur J Gyuaecol Oncol 2004; 25: 93-95.

Zeigler LD, Kroll SS: Primary breast cancer after prophylactic mastectomy. Am J Clin Oncol 1991; 14: 451-454.

Tempie WJ, et al.: Technical considerations for prophylactic mastectomy in patients at high risk for breast cancer. Am J Surg 1991; 161: 413-415.

Warner E, et al.: Compadson of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 2001; 19: 3524-3531.

Naród SA, et al.: Orał contraceptives and the risk of breast cancer in BRCAI and BRCA2 mutation carriers. J Nat! Cancer Inst 2002; 94: 1773-1779.

Byrski T, et al: Response to neo-adjuvant chemotherapy in women with f-positive breast cancers. Breast Cancer Res Treat 2008; 108: 289-296.

Lubiński J, et al.: Genetic contribution to all cancers: the fitst demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology. Breast Cancer Res Treat 2008 Apr 15.

Cybulski C, et al.: CHEK2-positive breast cancers in young Poiish women. Clin Cancer Res 2006; 12: 4832-4835.

Cybulski C, et al.: A deletion in CHEK2 of 5,395 bp predisposes lo breast cancer in Poland. Breast Cancer Res Treat 2007; 102:119-122.

Huzarski T, et al: Pathology of breast cancer in wometi with constitutional CHEK2 mutations. Breast Cancer Res Treat 2005; 90: 187-189.

Steffen J, et al: Germline mutations 657del5 of the NBS l gene contribute sigtiiftcantly to the incidence of breast cancer in Central Poland. tnt J Cancer 2006: 119: 472-475.

Górski B, et al.: Germline 657del5 mutation in the NBS i gene in breast cancer patients. Int J Cancer 2003; 106:379-381.

Huzarski T, et al: The 3020insC allele of NOD2 predisposes to eatly onset breast cancer. Breast Cancer Res Treat 2005; 89: 91-93. 69. Górski B, Naród SA, Lubiński J: A common missense variant in BRCA2 predisposes to early onset breast cancer. Breast Cancer Res 2005; 7: R1023-R1027.

Menkiszak J, et al.: Clinicai features of familial ovarian cancer lacking mutations in BRCAI or BRCA2. Eur J Gynaecol Oncol 2004; 25: 99-100.

Hart WR: Mucinous tumors of the ovary: A review. Int J Gyuecol Pathol 2005; 24: 4-25.

Shilr IeM, Kurman RJ: Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am S Pathol 2004; 164: 1511-1518.

Szymańska A: Identyfikacja genów związanych z predyspozycji do gruczoiako-torbielaków oeluzowych jajnika. Doctofs thesis. Pomorska Akademia Medyczna, Szczecin 2006.

Szymańska-Pa5temak J: Identyfikacja genów związanych z predyspozycją do gruczoiako-torbielaków surowiczych jajnika. Doctofs thesis. Pomorska Akademia Medyczna, Szczecin 2007.

77

Wyszukiwarka

Podobne podstrony:
25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 mruczus.jedzenie =
31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. Rys. S2 Podać wzór na
.31 .32 .33 .34 .35 36 .37 .38 .39 .40 .41 .42 43 RADA KÓŁ NAUKOWYCH Koto Naukowe
Poznaj C++ w$ godziny0114 Więcej o klasach 101 32 33 34:    < 35 36 37 38 39 40 41
P7092597 %,■ L r 18 19 20 21 l 35 36 37 38 39 40 41 42 43 44 45 8 Nakrętka M 10 CSN 02 1802.29
s11 iei wutniaki tu. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. Reakcje substratowe
8111 161454 Kinm: 1 2 18 19 20 21 22 23 24 <25) 26 27 ?B 29 30 31 32 33 34 35 36 37 38 3 4
bez tytułu48 Inflacja 259 22*. N, 23*. P, 24. P. 25. N. 26. N, 27. N, 28. P, 29. N. 30*. P, 31. N, 3
W11 2 23 23 24 25 20 27 20 29 30 31 32 33 34 35 36 37 31 » Jeże* podczas ałsfclrolery
P8022920 60 X 129 31 32 33 34 35 36 37 38 39/    / 4141 42 43 44 Ol Plartel.ń Mliezpl

więcej podobnych podstron